86 related articles for article (PubMed ID: 38619641)
21. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance.
Wu L; Brzostek J; Sakthi Vale PD; Wei Q; Koh CKT; Ong JXH; Wu LZ; Tan JC; Chua YL; Yap J; Song Y; Tan VJY; Tan TYY; Lai J; MacAry PA; Gascoigne NRJ
Cell Rep Med; 2023 Feb; 4(2):100917. PubMed ID: 36696897
[TBL] [Abstract][Full Text] [Related]
22. Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes.
Pandit H; Valentin A; Angel M; Deleage C; Bergamaschi C; Bear J; Sowder R; Felber BK; Pavlakis GN
iScience; 2023 Feb; 26(2):105929. PubMed ID: 36685042
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
24. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells.
Li L; Li Q; Yan ZX; Sheng LS; Fu D; Xu P; Wang L; Zhao WL
Sci Rep; 2022 Jul; 12(1):12506. PubMed ID: 35869100
[TBL] [Abstract][Full Text] [Related]
25. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome.
Arcangeli S; Bove C; Mezzanotte C; Camisa B; Falcone L; Manfredi F; Bezzecchi E; El Khoury R; Norata R; Sanvito F; Ponzoni M; Greco B; Moresco MA; Carrabba MG; Ciceri F; Bonini C; Bondanza A; Casucci M
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503659
[TBL] [Abstract][Full Text] [Related]
26. FDA approves second BCMA-targeted CAR-T cell therapy.
Mullard A
Nat Rev Drug Discov; 2022 Apr; 21(4):249. PubMed ID: 35277677
[No Abstract] [Full Text] [Related]
27. Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy.
McNerney KO; DiNofia AM; Teachey DT; Grupp SA; Maude SL
Blood Cancer Discov; 2022 Mar; 3(2):90-94. PubMed ID: 35015687
[TBL] [Abstract][Full Text] [Related]
28. Expression characteristic of
Zhang W; Zhang L; Qian J; Lin J; Chen Q; Yuan Q; Zhou J; Zhang T; Shi J; Zhou H
Bioengineered; 2021 Dec; 12(2):11987-12002. PubMed ID: 34787059
[No Abstract] [Full Text] [Related]
29. IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors.
Li G; Zhang Q; Han Z; Zhu Y; Shen H; Liu Z; Zhou Z; Ding W; Han S; He J; Yin Z; Zhou J; Ou R; Luo M; Liu S
Front Oncol; 2021; 11():734593. PubMed ID: 34778046
[TBL] [Abstract][Full Text] [Related]
30. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
[TBL] [Abstract][Full Text] [Related]
31. An overview of CAR T-cell clinical trial activity to 2021.
Adami A; Maher J
Immunother Adv; 2021 Jan; 1(1):ltab004. PubMed ID: 34056638
[TBL] [Abstract][Full Text] [Related]
32. Metabolic reprogramming of terminally exhausted CD8
Guo Y; Xie YQ; Gao M; Zhao Y; Franco F; Wenes M; Siddiqui I; Bevilacqua A; Wang H; Yang H; Feng B; Xie X; Sabatel CM; Tschumi B; Chaiboonchoe A; Wang Y; Li W; Xiao W; Held W; Romero P; Ho PC; Tang L
Nat Immunol; 2021 Jun; 22(6):746-756. PubMed ID: 34031618
[TBL] [Abstract][Full Text] [Related]
33. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
34. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
Moghimi B; Muthugounder S; Jambon S; Tibbetts R; Hung L; Bassiri H; Hogarty MD; Barrett DM; Shimada H; Asgharzadeh S
Nat Commun; 2021 Jan; 12(1):511. PubMed ID: 33479234
[TBL] [Abstract][Full Text] [Related]
35. The updated landscape of tumor microenvironment and drug repurposing.
Jin MZ; Jin WL
Signal Transduct Target Ther; 2020 Aug; 5(1):166. PubMed ID: 32843638
[TBL] [Abstract][Full Text] [Related]
36. The tumor microenvironment.
Anderson NM; Simon MC
Curr Biol; 2020 Aug; 30(16):R921-R925. PubMed ID: 32810447
[TBL] [Abstract][Full Text] [Related]
37. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
[TBL] [Abstract][Full Text] [Related]
38. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
[TBL] [Abstract][Full Text] [Related]
39. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.
Theruvath J; Sotillo E; Mount CW; Graef CM; Delaidelli A; Heitzeneder S; Labanieh L; Dhingra S; Leruste A; Majzner RG; Xu P; Mueller S; Yecies DW; Finetti MA; Williamson D; Johann PD; Kool M; Pfister S; Hasselblatt M; Frühwald MC; Delattre O; Surdez D; Bourdeaut F; Puget S; Zaidi S; Mitra SS; Cheshier S; Sorensen PH; Monje M; Mackall CL
Nat Med; 2020 May; 26(5):712-719. PubMed ID: 32341579
[TBL] [Abstract][Full Text] [Related]
40. Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer.
Zhao Z; Li Y; Liu W; Li X
Biomed Res Int; 2020; 2020():4795171. PubMed ID: 31998790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
